Sera Prognostics, Inc. (NASDAQ:SERA) Director Joshua Phillips Sells 12,710 Shares

Sera Prognostics, Inc. (NASDAQ:SERA) Director Joshua Phillips sold 12,710 shares of the business’s stock in a transaction on Friday, January 10th. The shares were sold at an average price of $7.40, for a total transaction of $94,054.00. Following the sale, the director now owns 5 shares in the company, valued at approximately $37. This trade represents a 99.96 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link.

Joshua Phillips also recently made the following trade(s):

• On Monday, January 13th, Joshua Phillips sold 12,163 shares of Sera Prognostics stock. The shares were sold at an average price of $6.39, for a total transaction of $77,721.57.

Sera Prognostics Stock Performance

Shares of SERA opened at $6.37 on Wednesday. Sera Prognostics, Inc. has a fifty-two week low of $4.98 and a fifty-two week high of $12.35. The firm’s 50-day simple moving average is $7.44 and its two-hundred day simple moving average is $7.31. The stock has a market cap of $215.13 million, a PE ratio of -6.43 and a beta of 0.86.

Sera Prognostics (NASDAQ:SERA) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.02). The company had revenue of $0.03 million for the quarter, compared to the consensus estimate of $0.09 million. During the same period in the prior year, the business earned ($0.23) earnings per share. Equities research analysts predict that Sera Prognostics, Inc. will post -0.96 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in SERA. Quest Partners LLC boosted its holdings in Sera Prognostics by 533.5% in the third quarter. Quest Partners LLC now owns 6,430 shares of the company’s stock worth $50,000 after purchasing an additional 5,415 shares during the last quarter. SG Americas Securities LLC purchased a new stake in Sera Prognostics during the 3rd quarter valued at $78,000. The Manufacturers Life Insurance Company bought a new position in shares of Sera Prognostics during the 2nd quarter valued at $68,000. Prime Capital Investment Advisors LLC purchased a new position in shares of Sera Prognostics in the 3rd quarter worth $104,000. Finally, Pallas Capital Advisors LLC bought a new stake in shares of Sera Prognostics in the fourth quarter worth $113,000. 54.64% of the stock is owned by hedge funds and other institutional investors.

Sera Prognostics Company Profile

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.